Carisa Liew
Neurology · Houston, TXNPI 1306077060
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,185 of the $4,877 with a category attached, or 85.8%. 37 manufacturers reported payments, led by AbbVie at 34.9% of the total. Reporting peaked in 2020 at $1,682 and has fallen 82.5% since, to $295 in 2025.
Across 208 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Medtronic$764
- Teva Pharmaceuticals USA, Inc.$394
- Amgen$230
- UCB, Inc.$149
- Biogen$127
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$681%
- Travel & lodging$62413%
- Food & beverage$4,18586%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $1,703 |
| Medtronic | 7 | $764 |
| Teva Pharmaceuticals USA, Inc. | 28 | $394 |
| Amgen(2 entities) | 8 | $230 |
| UCB, Inc. | 6 | $149 |
| Biogen | 3 | $127 |
| Abbott | 6 | $127 |
| Genentech USA, Inc. | 6 | $126 |
| Greenwich Biosciences, Inc. | 1 | $120 |
| EMD Serono, Inc. | 1 | $117 |
| Acadia Pharmaceuticals Inc | 7 | $113 |
| Acorda Therapeutics, Inc | 3 | $68 |
| SK Life Science, Inc. | 4 | $61 |
| Lilly USA, LLC | 4 | $60 |
| Assertio Therapeutics, Inc. | 3 | $56 |
| Zyla Life Sciences, Inc. | 3 | $56 |
| MDD US Operations, LLC | 4 | $53 |
| AstraZeneca | 2 | $50 |
| Upsher-smith Laboratories LLC | 3 | $46 |
| Merz North America, Inc. | 2 | $43 |
| Sanofi | 2 | $42 |
| Neurelis, Inc. | 2 | $39 |
| Bausch Health US, LLC | 2 | $34 |
| Argenx US, Inc. | 1 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Pfizer | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| TG Therapeutics, Inc. | 1 | $24 |
| GE HealthCare | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Fujirebio Diagnostics, Incorporated | 1 | $15 |
| Insightec,inc | 1 | $14 |
| Aquestive Therapeutics, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,877 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlatopaGlatiramer Acetate | 14 | $38,633 |
| Nurtec OdtRimegepant Sulfate | 21 | $29,723 |
| QuliptaAtogepant | 15 | $21,746 |
| UbrelvyUbrogepant | 17 | $18,315 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $17,671 |
| Rivastigmine | 46 | $15,231 |
| Memantine Hcl | 84 | $10,135 |
| Donepezil Hcl | 327 | $7,412 |
| Duloxetine Hcl | 76 | $6,882 |
| Levetiracetam | 137 | $4,598 |
| Memantine Hcl ErMemantine Hcl | 16 | $2,844 |
| RivastigmineRivastigmine Tartrate | 30 | $2,817 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 58 | $2,802 |
| Levetiracetam ErLevetiracetam | 24 | $2,498 |
| Gabapentin | 227 | $2,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $1,703 | $40,06132 claims |
| PfizerNurtec Odt | $26 | $29,72321 claims |
| Upsher-smith Laboratories LLCTopiramate | $46 | $98650 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- William OndoHouston$1.4M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.